A combinatorial smoothness criterion for spherical varieties

We suggest a combinatorial criterion for the smoothness of an arbitrary spherical variety using the classification of multiplicity-free spaces, generalizing an earlier result of Camus for spherical varieties of type $A$.Comment: 14 pages, 2 table

Lactadherin blocks thrombosis and hemostasis in vivo : correlation with platelet phosphatidylserine exposure

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/73556/1/j.1538-7836.2008.03010.x.pd

Lunar Exploration Orbiter (LEO): Providing a Globally Covered, Highly Resolved, Integrated Geological, Geochemical and Gephysical Data Base of the Moon

The German initiative for the Lunar Exploration Orbiter (LEO) originated from the national conference “Exploration of our Solar System”, held in Dresden in November 2006. Major result of this conference was that the Moon is of high interest for the scientific community for various reasons, it is affordable to perform an orbiting mission to Moon and it insures technological and scientific progress necessary to assist further exploration activities of our Solar System. Based on scientific proposals elaborated by 50 German scientists in January 2007, a preliminary payload of 12 instruments was defined. Further analysis were initated by DLR in the frame of two industry contracts, to perform a phase-zero mission definition. The Moon, our next neighbour in the Solar System is the first choice to learn, how to work and live without the chance of immediate support from earth and to get prepared for further and farther exploration missions. We have to improve our scientific knowledge base with respect to the Moon applying modern and state of the art research tools and methods. LEO is planed to be launched in 2012 and shall orbit the Moon for about four years in a low altitude orbit

A Seven-Marker Signature and Clinical Outcome in Malignant Melanoma: A Large-Scale Tissue-Microarray Study with Two Independent Patient Cohorts

Current staging methods such as tumor thickness, ulceration and invasion of the sentinel node are known to be prognostic parameters in patients with malignant melanoma (MM). However, predictive molecular marker profiles for risk stratification and therapy optimization are not yet available for routine clinical assessment.; Using tissue microarrays, we retrospectively analyzed samples from 364 patients with primary MM. We investigated a panel of 70 immunohistochemical (IHC) antibodies for cell cycle, apoptosis, DNA mismatch repair, differentiation, proliferation, cell adhesion, signaling and metabolism. A marker selection procedure based on univariate Cox regression and multiple testing correction was employed to correlate the IHC expression data with the clinical follow-up (overall and recurrence-free survival). The model was thoroughly evaluated with two different cross validation experiments, a permutation test and a multivariate Cox regression analysis. In addition, the predictive power of the identified marker signature was validated on a second independent external test cohort (n?=?225). A signature of seven biomarkers (Bax, Bcl-X, PTEN, COX-2, loss of ?-Catenin, loss of MTAP, and presence of CD20 positive B-lymphocytes) was found to be an independent negative predictor for overall and recurrence-free survival in patients with MM. The seven-marker signature could also predict a high risk of disease recurrence in patients with localized primary MM stage pT1-2 (tumor thickness ?2.00 mm). In particular, three of these markers (MTAP, COX-2, Bcl-X) were shown to offer direct therapeutic implications.; The seven-marker signature might serve as a prognostic tool enabling physicians to selectively triage, at the time of diagnosis, the subset of high recurrence risk stage I-II patients for adjuvant therapy. Selective treatment of those patients that are more likely to develop distant metastatic disease could potentially lower the burden of untreatable metastatic melanoma and revolutionize the therapeutic management of MM